Today's Stock Analyst Upgrades

Company	Action	Brokerage	Analyst	Current Price	Price Target	Rating
ALVO Alvotech	Upgraded by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Glen Santangelo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$5.35 +6.5%	$4.00 ➝ $8.00	Underweight ➝ Overweight
AMADY Amadeus IT Group	Upgraded by	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$63.97 +2.7%		Buy
BAP Credicorp	Upgraded by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yuri Fernandes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$383.99 +3.0%	$453.00 ➝ $482.00	Neutral ➝ Overweight
BUD Anheuser-Busch InBev SA/NV	Upgraded by	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$80.08 +0.8%		Hold ➝ Buy
INTC Intel	Upgraded by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tom O'Malley Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$101.70 +4.7%		Underperform ➝ Overweight
PAYX Paychex	Upgraded by	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Darrin Peller Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$117.40 -0.8%		Underperform ➝ Peer Perform
RCKT Rocket Pharmaceuticals	Upgraded by	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gil Blum Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$3.47 +1.6%	$9.00	Hold ➝ Buy
SMWB Similarweb	Upgraded by	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Scott Berg Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$8.37 -1.2%	$11.00	Hold ➝ Buy
SUNB Sunbelt Rentals Holdings, Inc. Common Stock	Upgraded by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Karl Green Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$73.26 +1.9%		Sector Perform ➝ Outperform
UNP Union Pacific	Upgraded by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Walter Spracklin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$282.62 -0.5%		Outperform ➝ Buy
NNVC on Alert: FDA Validation and Outperform Rating! (Ad) NanoViricides (NYSE: NNVC) just landed FDA Rare Pediatric Disease Designation for NV-387 in Measles, adding to its existing Orphan Drug Designation and opening a path toward a Priority Review Voucher, assets that have recently sold for around 195 million dollars. Noble Capital Markets initiated coverage with an Outperform rating and a 6 dollar price target, citing NNVC's broad-spectrum nanoviricide technology and its potential across Measles, MPox, Smallpox, and Ebola, where a Phase II trial is advancing in the Democratic Republic of Congo. See why analysts are watching NNVC's antiviral pipeline now
UNP Union Pacific	Upgraded by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Thomas Wadewitz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$282.62 -0.5%	$310.00 ➝ $339.00	Neutral ➝ Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 01:08 PM ET.

Frequently Asked Questions

Analyst ratings are the "buy" and "sell" labels, plus price targets, that investment researchers attach to specific securities. These ratings are based on financial data, earnings reports and conversations with company executives.

Analyst ratings provide plenty of helpful information, but you shouldn't use an analyst's "buy" rating as the sole reason you purchase a security. Analysts aren't immune to conflicts of interest or outside parties' influence, so ensure you always understand why a stock was labeled a "buy" or "sell."

Ratings give investors the analyst's overall opinion about a particular stock and price targets based on the company's valuation and prospects. Analysts often attend conference calls, ask questions and provide in-depth information about companies that are difficult to acquire elsewhere.

Stock Analyst Upgrades

Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Stock Analyst Upgrades

Frequently Asked Questions

What are analyst ratings?

Should you trust analyst ratings?

What does an analyst rating tell you about a stock?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools